On Thursday, Oppenheimer reiterated its Outperform rating on shares of Neurocrine (NASDAQ:NBIX) Biosciences (NASDAQ:NBIX), currently trading at $141.24, with a steady price target of $192.00. The firm ...

On Thursday, Oppenheimer reiterated its Outperform rating on shares of Neurocrine (NASDAQ:NBIX) Biosciences (NASDAQ:NBIX), currently trading at $141.24, with a steady price target of $192.00.

Neurocrine Bioscience Inc. said in a federal lawsuit that Spruce Biosciences Inc. is threatening patent litigation over its new rare disease drug Crenessity due to a “desperate need for cash”.

Researchers at Durham University have successfully demonstrated long-lasting quantum entanglement between molecules, opening new doors for future advancements in quantum computing, sensing ...

BMO Capital analyst Evan Seigerman maintained a Hold rating on Neurocrine (NBIX – Research Report) yesterday and set a price target of $121.00. Discover outperforming stocks and invest smarter ...

“It is extremely encouraging to see the progress being made by Neurocrine across this exciting portfolio of muscarinic agonists and its team’s clear commitment to advancing these novel ...

“It is extremely encouraging to see the progress being made by Neurocrine across this exciting portfolio of muscarinic agonists and its team’s clear commitment to advancing these novel molecules ...